PT-141, also known by the approved drug name Bremelanotide, acts on melanocortin receptors in the brain and is used to address low sexual desire. Unlike most other entries in this category, it has gone through formal drug approval for a specific indication in some markets.
As Bremelanotide, it has been through clinical trials and received regulatory approval (in the US, under the brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women, a genuinely evidence-backed use. Products sold as PT-141 research chemical outside this regulated pathway are a different matter entirely: unverified sourcing, dosing and quality.
Approved use, through a prescriber, has a known clinical safety and side effect profile including nausea and blood pressure changes. Unregulated research chemical versions carry the additional risk of unverified purity and dosing on top of the drug's known effects.
Legal and research status: as Bremelanotide, this has formal drug approval for a specific indication in some markets, but is not approved in the UK for general use, and any legitimate use should go through a prescriber, not an unregulated research chemical source. If low sexual desire is a concern, a doctor can discuss appropriate, evidence-based options.
Where approved and prescribed, cost follows standard prescription pricing. Unregulated online versions are priced per vial with no quality assurance.
FDA approval documentation for Bremelanotide (Vyleesi). Clinical trial evidence for hypoactive sexual desire disorder. Educational information only.